Figure 5.
Long-term change in facial volume loss (cheeks) with Belotero® Volume treatment based on the investigators’ rating on the Facial Volume Loss Scale.
Notes: The difference from baseline was tested by Micheels et al46 and was statistically significant at each time point (P<0.0001). The mean trend shows the average scores when pooling data from the two studies. In Micheels et al’s study,47 other facial areas than the cheeks were assessed. Only results for cheeks are presented here for comparison with Micheels et al.46 Assessments were performed at baseline, the day following the injection (ie, post-injection), and then at 1, 3, and 6 months. Touch-up at 1 month was performed in two out of 56 patients (3.6%).47 In Micheels et al’s study,46 assessments were performed at baseline, immediately post-injection, and then at 1, 3, 6, 9, and 12 months, with an optional follow-up at 18 months (n=11). Touch-up was performed in two out of 20 patients (10%, timing not provided).46 Baseline is before the injection. Reproduced from Micheels P, Ascher B, Beilin G, Elias B, Rummaneethorn P, Sattler G. Evaluation clinique de l’efficacité et l’innocuité d’un acide hyaluronique volumateur de technologie CPM® pour le traitement de multiples zones du visage [Clinical evaluation of the efficacy and safety of a hyaluronic acid volumizer with CPM® technology for the treatment of multiple facial areas]. Réal Thér Dermato-Vénérol. 2014;235(3):2–8. French.47 Micheels P, Vandeputte J, Kravtsov M. Treatment of age-related midface atrophy by injection of cohesive polydensified matrix hyaluronic acid volumizer. J Clin Aesthet Dermatol. 2015;8(3):28–34.46 Copyright ©2015 Matrix Medical Communications. All rights reserved.46
Abbreviations: FVLS, Facial Volume Loss Scale; t-u, touch-up allowed.